Ting-Chuan Wang

Ting-Chuan Wang

Auto-generated profile, based on publicly available information

Ting-Chuan Wang

Department of Medical Research, Integrative Medical Data Center, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
YHYi Wen Huang
Yi Wen Huang
CLChia-Long Lee
Chia-Long Lee
SYSien-Sing Yang
Sien-Sing Yang
SFSzu-Chieh Fu
Szu-Chieh Fu
YCYun-Yi Chen
Yun-Yi Chen
DCDing-Shinn Chen
Ding-Shinn Chen
The protective effect of statins in cirrhosis and its decompensation in chronic hepatitis B (CHB) patients remains unknown. We conducted a population-based cohort study using data from the Taiwanese National Health Insurance Research Database from 1997 to 2009. A total of 298,761 CHB patients were identified. CHB patients using statins (n=6,543; defined as ≥28 cumulative defined daily doses (cDDD)) and a 1:1 ratio propensity score and inception point (the date of first use of statins)-matched non-statins (<28 cDDD) were followed up from the inception point until the development of cirrhosis or its decompensation or until withdrawal from insurance or December 2009. After adjustment for competing mortality, CHB patients using statins had a significantly lower cumulative incidence of cirrhosis (relative risk)=0.433; 95% confidence interval (CI)=0.344-0.515; modified log-rank test, P<0.001) and decompensated cirrhosis (relative risk=0.468; 95% CI=0.344-0.637; P<0.001) compared with patients not using statins. After adjustment for age, gender, comorbidity index, hypertension, diabetes, hyperlipidemia, hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, aspirin use, diabetes medication, CHB treatment, non-statin lipid-lowering drugs, and triglyceride lipid-lowering drugs using the Cox proportional hazard model, statins were still an independent protector against cirrhosis (adjusted hazard ratio (AHR)=0.512; 95% CI=0.413-0.634; P<0.001) and its decompensation (AHR=0.534; 95% CI=0.433-0.659; P365 cDDD of statins, respectively. CHB patients who receive statin therapy have a dose-dependent reduction in the risk of cirrhosis and its decompensation.

11 June 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
YHYi Wen Huang
Yi Wen Huang
SYSien-Sing Yang
Sien-Sing Yang
SFSzu-Chieh Fu
Szu-Chieh Fu
TWTing-Chuan Wang
Ting-Chuan Wang
CHCheng-Kai Hsu
Cheng-Kai Hsu
JKJia-Horng Kao
Jia-Horng Kao
The effect of diabetes on cirrhosis, its decompensation, and their time relationship in chronic hepatitis C (CHC) patients remains unclear. We conducted a nation-wide cohort study by using the Taiwanese National Health Insurance Research Database, which is comprised of data from >99% of the entire population. Among having randomly sampled 1 million enrollees, 6,251 adult CHC patients were identified from 1997 to 2009. Diabetes was defined as new onset in CHC patients who were given the diagnosis in the years 1999-2003, but not in 1997-1998. The cohorts of CHC with new-onset diabetes (n = 424) and nondiabetes (n = 1,708) were followed up from inception point in diabetes and from year 1999 in the nondiabetes cohort until development of cirrhosis or its decompensation, withdrawal from insurance, or December 2009. Kaplan-Meier's survival analysis showed a significantly higher cumulative incidence of cirrhosis (relative risk [RR] = 1.53; 95% confidence interval [CI] = 1.11-2.11; log-rank test; P < 0.001) and decompensated cirrhosis (RR = 2.01; 95% CI = 1.07-3.79; log-rank test; P < 0.001) among patients with new-onset diabetes, as compared to those without. After adjustment for age, gender, CHC treatment, diabetes treatment, hepatocellular carcinoma, comorbidity index, hypertension, hyperlipidemia, and obesity by Cox's proportional hazard model, diabetes was still an independent predictor for cirrhosis (hazard ratio [HR] = 2.505; 95% CI = 1.609-3.897; P < 0.001) and its decompensation (HR = 3.560; 95% CI = 1.526-8.307; P = 0.003). Conclusion: CHC patients who develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time. (Hepatology 2014;60:807–814)

18 September 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
YHYi Wen Huang
Yi Wen Huang
TWTing-Chuan Wang
Ting-Chuan Wang
SLShih-Chang Lin
Shih-Chang Lin
HCHan-Yu Chang
Han-Yu Chang
DCDing-Shinn Chen
Ding-Shinn Chen
JKJia-Horng Kao
Jia-Horng Kao
Background. The impact of diabetes on cirrhosis, its decompensation, and their time relationship in patients with chronic hepatitis B (CHB) remain unclear. Methods. We conducted a nationwide cohort study by using the Taiwanese National Health Insurance Research Database, which was comprised of data from >99% of the entire population. Among 1 million randomly sampled enrollees, 14 523 adult CHB patients were identified from 1997 to 2009. Diabetes was defined as newly diagnosed in CHB patients who were given the diagnosis in the years 1998–2001 but not in 1996–1997 and with physician visits of at least twice per year. The cohorts of CHB with newly diagnosed diabetes (n = 351) and without diabetes (n = 7886) were followed up from the diagnosis of diabetes and from 2000 in the patients without diabetes until development of cirrhosis or its decompensation, withdrawal from insurance, or December 2009. Results. Kaplan-Meier survival analysis showed a significantly higher cumulative incidence of cirrhosis (relative risk [RR] = 3.43; 95% confidence interval [CI], 2.62–4.49; P < .001, log-rank test) and decompensated cirrhosis (RR = 4.11; 95% CI, 2.95–5.70; P < .001, log-rank test) among patients with newly developed diabetes compared with those without diabetes. After adjustment for age, sex, CHB treatment, hepatocellular carcinoma, and comorbidity index by Cox proportional hazards model, diabetes was still an independent predictor for cirrhosis (hazard ratio [HR] = 2.015; 95% CI, 1.393–2.915; P < .001) and its decompensation (HR = 1.792; 95% CI, 1.192–2.695; P = .005). Conclusions. Patients with CHB who develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time.

1 May 2014 in Antiviral Therapy
Verified
Journal Article
Closed access
YHYi Wen Huang
Yi Wen Huang
STShoichi Takahashi
Shoichi Takahashi
MTMasataka Tsuge
Masataka Tsuge
CCChi-Ling Chen
Chi-Ling Chen
TWTing-Chuan Wang
Ting-Chuan Wang
JKJia-Horng Kao
Jia-Horng Kao
Background: Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. Methods: Serum HBV RNA was quantified before and at 12 and 24 weeks of lamivudine or entecavir therapy. Serum HBV DNA was measured every 4–12 weeks during treatment to define initial virological response. Results: Serum HBV RNA was detectable in 21 of 52 (40%) consecutive patients with a mean of 5.2 log copies/ml (male/female 35/17, mean age of 60 years with a range of 31–82, 44% HBeAg-positive, and 26 with lamivudine and 26 with entecavir) before treatment. Serum HBV RNA level at week 12 in patients with an interval from detectable to undetectable serum HBV DNA level <16 weeks was significantly lower than those with an interval ≥16 weeks (3.8 +3.8 versus 6.6 +3.5 log copies/ ml, P=0.013). After adjustment for serum HBV DNA level at week 12, serum quantatitive HBsAg level at week 12 and pretreatment ALT level, low serum HBV RNA level at week 12 predicted a shorter interval to undetectable serum HBV DNA level (adjusted hazard ratio =0.908, 95% CI 0.829, 0.993, P=0.035). Conclusions: Low serum HBV RNA level at week 12 of nucleoside analogue therapy independently predicts initial virological response in treated chronic hepatitis B patients. Serum HBV RNA levels may thus be useful for optimizing treatment of chronic hepatitis B.

6 April 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SFS.‐C. Fu
S.‐C. Fu
YHYi Wen Huang
Yi Wen Huang
TWT.‐C. Wang
T.‐C. Wang
JHJ.‐T. Hu
J.‐T. Hu
DCD.‐S. Chen
D.‐S. Chen
SYS.‐S. Yang
S.‐S. Yang

1 March 2011 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
YLYing‐Ta Lai
Ying‐Ta Lai
TWTing‐Chuan Wang
Ting‐Chuan Wang
LCLi‐Ju Chuang
Li‐Ju Chuang
MCMing‐Hsu Chen
Ming‐Hsu Chen
PWPa‐Chun Wang
Pa‐Chun Wang